Yes, they've done it again. For me, this is the 6th or 7th dilutive event. Thankfully the raise was relatively small (approx. $50M ) and seems to have been relatively well absorbed. The battle between longs and shorts continues: A large short position remains intact on the issue while RJ Kirk scooped up a pretty good chunk of the latest financing.
No real news from the company recently. PICASSO III appears on track. Waiting to see if ZIOP has anything to bring to ASCO re: either their SCLC or synthetic biology programs.
Long ZIOP, TC. LGND, CRMD